Open Payments Explorer: How Much Industry Money Goes to Doctors and Teaching Hospitals

ProPublica

Journalism in the Public Interest

Cancel
Dollars for Docs

Open Payments Explorer

How Much Industry Money Goes to Doctors and Teaching Hospitals

By Lena Groeger, Ryann Grochowski Jones, Charles Ornstein and Mike Tigas, ProPublica, Jan. 7, 2015

Beginning in 2014, the federal government mandated that pharmaceutical and medical device manufacturers publicly report payments made to doctors and teaching hospitals. The first report covered the last five months of 2013. Use this tool to search for a company, drug or device--and compare it to another. Related: Vying for Market Share, Companies Heavily Promote “Me Too” Drugs »

Select a Company, Drug or Device

See how much money companies spend on interactions with doctors, excluding research and royalties. Search or select from the dropdown menu.

Companies

TOP COMPANIES

Company Name
Payments

Pfizer Inc.

$30M

Janssen Pharmaceuticals, Inc.

$20.5M

Astrazeneca Pharmaceuticals LP

$19.1M

Forest Laboratories, Inc.

$17.2M

Allergan Inc.

$15.5M

Otsuka America Pharmaceutical, Inc.

$15M

Sanofi and Genzyme Us Companies

$14.6M

AbbVie, Inc.

$13.5M

Genentech, Inc.

$12.9M

Intuitive Surgical, Inc.

$12.8M

Novo Nordisk Inc.

$12.4M

Depuy Synthes Sales Inc.

$12M

Bristol Myers Squibb Company

$11.9M

Eli Lilly and Company

$11.7M

Teva Pharmaceuticals USA, Inc.

$11.6M

Novartis Pharmaceuticals Corporation

$11.5M

Boehringer Ingelheim Pharmaceuticals, Inc.

$10.8M

Stryker Corporation

$10.3M

Merck Sharp & Dohme Corporation

$10.3M

Takeda Pharmaceuticals U.S.A., Inc.

$9.68M

Drugs

TOP DRUGS

Drug Name
Payments

VICTOZA

$9.07M

ELIQUIS

$7.99M

BRILINTA

$7.71M

INVOKANA

$7.16M

LATUDA

$7.03M

XARELTO

$6.93M

HUMIRA

$5.58M

TUDORZA

$5.31M

DALIRESP

$5.2M

ABILIFY MAINTENA

$5M

ABILIFY

$4.77M

LINZESS

$4.59M

PRADAXA

$4.43M

TRADJENTA

$4.17M

BELVIQ

$4.14M

COPAXONE

$4.01M

SAMSCA

$3.89M

H.P. ACTHAR

$3.62M

SYMBICORT

$3.5M

AUBAGIO

$3.37M

Devices

TOP DEVICES

Device Name
Payments

DA VINCI SURGICAL SYSTEM

$12.8M

HIPS

$9.42M

SPINAL FUSION DEVICE

$7.25M

SPINE

$5.84M

KNEES

$4.69M

DELIVERY SYSTEM

$4.35M

VASCULAR

$4.31M

DENTAL IMPLANTS

$3.16M

TRAUMA & EXTREMITIES

$2.89M

DENTAL CHAIR

$2.82M

THORACOLUMBAR

$2.65M

TRAUMA

$2.45M

ALLODERM

$2.29M

MAKOPLASTY

$2.01M

ORTHOPEDICS

$1.99M

CARDIAC RHYTHM MANAGEMENT

$1.96M

ARTHREX PRODUCT LINE DISTAL EXTREMITY ARTHROSCOPY

$1.95M

ALL ARTHREX PRODUCT LINES

$1.94M

PAIN MANAGEMENT

$1.89M

THORACOLUMBAR THERAPIES

$1.89M

NOTES

"Other" is not displayed in the top products list because it is an aggregation of multiple entries.

METHODOLOGY

This tool is based on Open Payments data released by the Centers for Medicare and Medicaid Services at the end of September, and does not include an updated version of the data released in mid-December.

Some companies misspelled the names of drugs and devices, which made it difficult to accurately tally spending. Others referred to their products by more than one name. Some companies listed their medical devices as drugs, while other companies reported payments to doctors or teaching hospitals, but left off which products were related to the payments.

When possible, we standardized drug and device names to allow for easier aggregation and comparisons. We also recategorized products when a company listed something as both a drug and a device or when a company appeared to make a mistake.

In some cases, companies reported multiple drugs associated with the same payment, without breaking out how much was attributable to each. Rather than guessing how to apportion such payments, ProPublica applied the full payment amount to each drug, which may result in higher tallies. (Some companies routinely listed multiple drugs with individual payments, so excluding such spending would have substantially distorted their totals.)

Some types of drug promotion don’t show up in the Open Payments data. These include the amount spent by companies on drug representatives who visit doctors’ offices, the value of drug samples left at those offices, and what’s spent on advertising to physicians and patients.

Because of data inconsistencies, about 40 percent of records in Open Payments do not contain the names of the specific physician or hospital that received the payment. The records do note the drug or device involved, and ProPublica included those in our analysis.

Additional design and development by Sisi Wei.